This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SOUTH PLAINFIELD, N.J.,
May 23, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will provide an update on the re-examination of its marketing authorization application to the European Medicines Agency (EMA) for conditional marketing authorization of Translarna
TM (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy. PTC will hold a conference call at
8:30 am ET on
Friday, May 23, 2014.
The call can be accessed by dialing (877) 303-9216 (toll-free) or (973) 935-8152 (international) five minutes prior to the start of the call and providing the passcode 51166480. A live, listen-only webcast of the conference call can be accessed on the investor relations section of the PTC website at
www.ptcbio.com. The call will be archived for two weeks following the presentation.
About PTC Therapeutics, Inc.
PTC is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and in collaborations with leading biopharmaceutical companies. For more information on the company, please visit our website
SOURCE PTC Therapeutics, Inc.